Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.Wall Street slid from record highs as President Donald Trump renewed tariff threats against China, rattling investor sentiment and triggering a pullback in export-sensitive and financial stocks. Regional bank credit concerns added fuel to the selloff, with reports of bad loans from Zions Bancorp (NASDAQ:ZION) and Western Alliance Bancorp (NYSE:WAL) sparking fear of deeper system ...

Ah, the stock market. A bastion of rational thought, predictable patterns, and calm, measured reactions. Or, at least, that’s what the textbooks tell us. In the era of Donald J. Trump, however, the market often resembles a particularly caffeinated toddler in a toy store – prone to sudden, dramatic shifts based on pronouncements that can, and frequently do, contradict earlier statements. The past week has been no exception, offering a masterclass in market gymnastics driven by the former (and potentially fut ...

As an example, in London, you'd buy a certain drug for $130 and even less than that, I guess $88 as of account a month ago. And in New York, you pay $1,300 for the same thing. So now we're going to be paying uh instead of 1300, you'll be paying about $150. And they'll be paying $150, too.We're going to pay the same thing. Favored nations. It's beautiful. It's a beautiful thing.and we've been ripped off by the whole world for a long period of time. >> You mentioned a $1,300 drug at the top of this. Were you ...

A U.S. jury on Friday returned a historic verdict against BNP Paribas , finding the French bank helped Sudan's government commit genocide by providing banking services that violated American sanctions... ...

智通财经APP获悉，周五，减肥药公司股价下跌，礼来(LLY.US)跌约2%；而销售低价配制版GLP-1的 Hims & Hers Health(HIMS.US)股价更大跌超15%。此前美国总统特朗普表示，其政府目标是将热门GLP- 1减肥药的品牌定价压低至每月150美元，远低于当前动辄超千美元的标价。 目前礼来及诺和诺德通过直销网站提供约月500美元的折扣版；Hims & Hers等远程医疗平台则提供配制 版，每月130-200美元不等。 特朗普表示："同一款药在伦敦一个月只要88至130美元，在纽约却要1300美元。将来你付150，我们也 付150，价格要一样。"当被追问指的是哪款药时，特朗普回答是热门减肥药Ozempic。 不过，美国医疗保险与医疗补助服务中心(CMS)署长Mehmet Oz当场澄清称，政府尚未与药企就GLP-1 议价达成协议，"我们还没谈妥，这一类药还没谈到"。此前一周，Oz表示政府正与减肥药厂商"进行大 量谈判"。 礼来与诺和诺德均是此前收到特朗普政府来函的17家大型药企之一，信件要求这些药商将美国药价与其 他发达国家对齐。辉瑞(PFE.US)和阿斯利康(AZN.US)已签署政府倡议达 ...

Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of their current list price."In London, you'd buy a certain drug for $130 and even less than that ... $88 as of... a month ago. And in New York, you pay $1,300 for the same thing," Trump said during a Thursday afternoon event about in vitro fertilization at the White House. "Instead of $1,300 you'll be paying about ...

When I last wrote about the obesity treatments' specialist Eli Lilly (NYSE: LLY ) in August, there was a 50% upside to the stock following its crash after disappointing drug trial results. In the two months since, the stock has realised ~30% of the upside farManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green econ ...

That was the president yesterday in a press conference with Dr. . Oz suggesting that out-of- pocket prices for Ozepic could soon be made lower. Shares of Eli Liy and Nova you can see under some pressure this morning as a result of those comments.Joining us now to break down the moveo healthc care strategist Jared Holes. So Jared, what do you make of those comments. What do they mean for either one of these key drug makers.>> Hey David, how are you. Um I'm not that surprised. I mean, this this seems like, yo ...

American Express shares climbed after the company posted strong quarterly results. Scott Olson / Staff / Getty Images Close Key Takeaways Major U.S. equities indexes climbed at midday Friday as regional bank stocks rebounded from yesterday's losses after a flurry of corporate earnings reports. The Dow, S&P 500, and Nasdaq were all higher. Kenvue (KVUE) was the best-performing stock in the S&P 500 as investors bought the dip in the health care product's stock following yesterday's selloff after a lawsuit in ...

Core Insights - Novo Nordisk (NVO) shares declined approximately 4% in pre-market trading following U.S. President Donald Trump's indication of potential significant price reductions for the company's GLP-1 RA drugs, Ozempic and Wegovy, which have been crucial for the company's growth [1][7] - Trump suggested that the prices of these drugs could decrease to around $150 out-of-pocket for Americans, although formal negotiations have not yet commenced [2][3] - The reduction in drug prices could enhance access for diabetes and obesity patients but raises concerns about the implications for drug development economics and future medical innovations [4][11] Company Performance - Year-to-date, NVO stock has dropped 34.7%, contrasting with a 5.5% growth in the industry [6] - The company has faced challenges with slowing uptake of Wegovy and increased competition from Eli Lilly, prompting a restructuring plan aimed at saving around DKK 8 billion by 2026 through workforce reductions [10][11] Competitive Landscape - Eli Lilly, a key competitor, has seen rapid demand for its tirzepatide-based drugs, Mounjaro and Zepbound, which generated combined sales of $14.7 billion in the first half of 2025, accounting for 52% of Lilly's total revenues [12] - Following Trump's comments, Eli Lilly's shares also fell about 4% in pre-market trading, indicating investor concerns regarding similar pricing pressures for its GLP-1 therapies [13] Market Dynamics - The potential price cuts for GLP-1 drugs could deter pharmaceutical companies from investing in research and development, impacting future innovations in the industry [11]